Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...